Implementation of Regulatory Guidance for JAK Inhibitors Use in Patients with Immune-Mediated Inflammatory Diseases: An International Appropriateness Study
Autoimmun Rev. 2023;23(3):103504 doi: 10.1016/j.autrev.2023.103504 Epub ahead of print
In this two-round modified RAM study by Solitano, et al., the authors found that experts preferred to assess JAK inhibitor risk on a case-by-case basis across all specialties. Uncertainty remained on several clinical scenarios regarding the appropriate use of JAK inhibitors, however they remain an important therapy option for the treatment of IMIDs and were deemed appropriate for patients with moderate risk profiles.
A panel of 21 subject matter experts assessed the suitability of JAK inhibitor therapies for 27 predesigned clinical vignettes with the aim of creating regulatory guideline recommendations. Each vignette described an individual gastroenterology, dermatology, or rheumatology patient with associated risks, and the appropriateness of JAK inhibitor therapy was determined. Further guidance on JAK inhibitor therapy can inform IMID treatment on an individual basis, and lead toward more targeted treatment.
